OBJECTIVE To examine the impact of fenigidin treatment regimen on peripheral hemodynamics in patients with stable angina pectoris of effort and postinfarction cardiosclerosis without signs of heart failure. METHODS Thirty two patients with functional classes II and III stable angina of effort and 32 with postinfarction cardiosclerosis without signs of heart failure were examined. RESULTS Monotherapy with fenigidin, 30-40 mg/day in patients with stable angina pectoris of effort and in those with postinfarction cardiosclerosis lowered systolic and mean blood pressures, total and specific peripheral vascular resistance, venous tone and increased additional venous volume and maximum vein emptying rate in the upper and lower extremities. Fenigidin therapy caused no side effects. CONCLUSIONS Fenigidin monotherapy improves hemodynamic parameters in stable angina pectoris of effort and postinfarction cardiosclerosis without obvious signs of heart failure and causes no side effects when the drug is used in a dose of 30-40 mg/day for 3 weeks.